"The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.
Caution should be exercised to prevent inadvertent overdosage with PLATINOL.
Acute overdosage with this drug may result in kidney failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, intractable nausea and vomiting and/or neuritis. In addition, death can occur following overdosage.
No proven antidotes have been established for PLATINOL overdosage. Hemodialysis, even when initiated four hours after the overdosage, appears to have little effect on removing platinum from the body because of PLATINOL's rapid and high degree of protein binding. Management of overdosage should include general supportive measures to sustain the patient through any period of toxicity that may occur.
PLATINOL is contraindicated in patients with preexisting renal impairment. PLATINOL should not be employed in myelosuppressed patients, or in patients with hearing impairment.
PLATINOL is contraindicated in patients with a history of allergic reactions to PLATINOL or other platinum-containing compounds.
Last reviewed on RxList: 1/24/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Platinol Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.